<DOC>
	<DOCNO>NCT02986854</DOCNO>
	<brief_summary>The purpose/aim study assess safety antibody response vaccination booster dose Menveo give 4-6 year primary MenACWY vaccination ass safety antibody response single dose Menveo give vaccine-naïve subject</brief_summary>
	<brief_title>Study Assess Safety Immunogenicity Single Dose GlaxoSmithKline 's ( GSK ) Meningococcal MenACWY-CRM Vaccine ( Menveo ) , Administered Subjects 15 Through 55 Years Age , Approximately 4-6 Years After Primary ACWY Vaccination</brief_title>
	<detailed_description>This phase 3b , control , open-label , multi-center study evaluate safety immunogenicity Menveo single vaccination healthy individual vaccinate Menveo Menactra 4 6 year vaccine-naive individual . Vaccine-naive subject : subject receive meningococcal vaccine prior participation clinical trial . Subjects randomise one two different blood draw schedule accord 1:1 ratio . - Blood draw Day 1 , Day 4 Day 29 - Blood draw Day 1 , Day 6 Day 29</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Individuals 15 55 year age day inform consent assent . 2 . Individuals receive Menveo 4 6 year prior enrolment age 11 year old OR Individuals receive Menactra 4 6 year prior enrolment age 11 year old OR Individuals receive previous meningococcal vaccine . 3 . Individuals voluntarily give write informed consent nature study explain accord local regulatory requirement , prior study entry . If subject age 18 time enrolment , parent ( ) /legal guardian ( ) subject voluntarily give write informed consent . 4 . Individuals comply study procedure include followup . 5 . Males Or Females nonchildbearing potential Or Females childbearing potential use effective birth control method intend use least 30 day study vaccination . Each subject must : 1 . History meningococcal vaccine administration single vaccination give 4 6 year OR History meningococcal vaccine administration . 2 . Current previous , confirm suspected disease cause N. meningitidis . 3 . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis infection within 60 day prior study vaccination . 4 . Progressive , unstable uncontrolled clinical condition . 5 . Hypersensitivity , include allergy , component vaccine , medicinal product medical equipment whose use foreseen study . 6 . Clinical condition represent contraindication intramuscular vaccination ( IM ) blood draw . 7 . Abnormal function immune system result : 1 . Clinical condition . 2 . Systemic administration corticosteroid 14 consecutive day within 90 day prior study vaccination . 3 . Administration antineoplastic immunomodulating agent radiotherapy within 90 day prior study vaccination . 8 . Received immunoglobulin blood product within 180 day prior informed consent . 9 . Received systemic antibiotic treatment within 3 day prior study vaccination blood draw . 10 . Received investigational nonregistered medicinal product within 30 day prior study vaccination . 11 . Study personnel immediate family household member . 12 . Individuals receive vaccine within 7 day 14 day prior vaccination study plan receive vaccine within 28 day study vaccination . 13 . Individuals experience moderate severe acute infection and/or fever define temperature ≥38°C ( 100.4°F ) within 3 day prior study vaccination . 14 . Any clinical condition , opinion investigator , might pose additional risk subject due participation study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Meningococcal disease</keyword>
	<keyword>Booster vaccination</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Antibody persistence</keyword>
</DOC>